Votrient

Indicated For

renal cell carcinoma, soft tissue sarcoma

About This Medication

# Finding Affordable Access to Votrient (Pazopanib) ## Important Information About Votrient Assistance Currently, there is no active manufacturer prescription assistance program (PAP) directly from Votrient's manufacturer. However, this guide will help you explore all available options to access this important medication at reduced or no cost. ## About Votrient (Pazopanib) Votrient is a targeted cancer medication used to treat: - **Renal cell carcinoma** (kidney cancer) - **Soft tissue sarcoma** (a type of connective tissue cancer) Votrient is a tyrosine kinase inhibitor, which means it works by blocking proteins that help cancer cells grow and spread. Because this is a specialized cancer medication, finding affordable access is crucial for many patients. ## Why No Active Manufacturer Program? Manufacturers sometimes discontinue or consolidate assistance programs. When this happens, patients have several alternative resources available. ## Alternative Ways to Get Help Paying for Votrient ### 1. **Patient Assistance Organizations** These non-profit organizations help patients access medications they cannot afford: - **NeedyMeds.org**: Comprehensive database of free/low-cost medication programs - **Patient Advocate Foundation**: Copay assistance and emergency financial grants - **CancerCare**: Financial assistance specifically for cancer patients - **American Cancer Society**: Local resources and medication access programs - **Leukemia & Lymphoma Society**: Medication co-pay assistance programs These organizations typically: - Have no income requirements or flexible thresholds - Process applications within 2-4 weeks - Provide ongoing support and reauthorization - Can help with copays, deductibles, and uninsured costs ### 2. **Insurance-Based Resources** **If you have private insurance:** - Contact your insurance company about copay assistance programs - Ask about specialty pharmacy networks that may offer discounts - Check if generic pazopanib is covered (often less expensive) - Request prior authorization reviews if denied **If you have Medicare:** - Explore Medicare Part D "Extra Help" program for prescription costs - Ask about manufacturer programs through your Medicare plan - Investigate state Pharmaceutical Assistance Programs (PAPs) **If you are uninsured:** - Contact local health departments about uninsured patient programs - Ask your oncologist about hospital-based assistance programs - Explore state-specific medication assistance programs ### 3. **State Pharmaceutical Assistance Programs** Most states have programs helping uninsured or underinsured residents access medications: - Income limits vary by state (typically $20,000-$50,000 annually) - Coverage may include full or partial medication costs - Contact your state health department for eligibility ### 4. **Generic Pazopanib** Generic versions of Votrient may be significantly cheaper: - Ask your doctor if generic pazopanib is appropriate for your treatment - Generic versions are often 30-50% less expensive - Many insurance plans cover generics at lower copays - Discuss with your oncology team about switching if cost is a barrier ### 5. **Hospital and Clinic Assistance** Many cancer treatment centers have: - Social workers who specialize in medication access - In-house assistance programs - Relationships with manufacturers and assistance organizations - Emergency medication supplies for financial hardship cases **Ask your oncology clinic about these resources before leaving your appointment.** ## Income Eligibility Guidelines While the manufacturer program is inactive, assistance organizations typically use these general income thresholds (these vary by program): | Household Size | Maximum Annual Income | |---|---| | 1 person | $20,000 - $35,000 | | 2 people | $27,000 - $47,000 | | 3 people | $34,000 - $59,000 | | 4 people | $41,000 - $71,000 | | 5 people | $48,000 - $83,000 | | 6 people | $55,000 - $95,000 | *Note: Many organizations use flexible criteria and don't strictly enforce income limits for cancer patients. Always apply even if you're above these thresholds.* ## Insurance Requirements Most assistance organizations: - Work with insured, underinsured, and uninsured patients - Do NOT require private insurance - Accept Medicare and Medicaid patients - Have no specific insurance requirements ## Step-by-Step Application Instructions ### Step 1: Gather Required Documents - Valid prescription for Votrient from your oncologist - Proof of income (recent tax return, pay stubs, or benefit statements) - Proof of citizenship or legal residency - Insurance card (if applicable) - Identification (driver's license or state ID) ### Step 2: Choose Your Resources 1. Start with your oncology clinic's social worker 2. Contact 2-3 organizations from the list above 3. Apply to state PAP if you qualify 4. Ask about generic pazopanib cost at your pharmacy ### Step 3: Complete Applications - Most organizations offer online, phone, or mail applications - Provide accurate financial information - Include detailed prescription information - Add a brief explanation of financial hardship if requested ### Step 4: Submit Documentation - Mail, fax, or upload documents as instructed - Keep copies for your records - Note submission dates and confirmation numbers ### Step 5: Follow Up - Call 1-2 weeks after submission if no confirmation - Check email regularly for updates - Respond promptly to any requests for additional information ## Timeline and Delivery - **Typical Processing Time**: 4-8 weeks (varies by organization) - **Expedited Options**: Some organizations offer faster processing (1-2 weeks) for urgent cases - **Delivery Method**: Usually sent directly to your pharmacy; some mail to your home - **Frequency**: Most programs provide 30-90 day supplies; reauthorization needed for continued access ## What If You're Denied? If one organization denies your application: - Don't give up—apply to multiple organizations - Ask why you were denied and if you can reapply - Provide additional financial documentation if available - Ask your oncologist to contact the organization on your behalf - Try a different organization with different eligibility criteria ## Reauthorization and Ongoing Assistance Most programs require periodic reauthorization: - You'll receive notices when reauthorization is needed - Usually required annually or every 6 months - Same application process repeats - Some organizations allow auto-renewal ## Additional Resources **CancerCare**: 1-800-813-4673 **American Cancer Society**: 1-800-227-2345 **Patient Advocate Foundation**: 1-800-532-5274 **NeedyMeds.org**: Visit website for comprehensive program database **Your Oncology Social Worker**: Free, in-person assistance ## Practical Tips for Success 1. **Start Early**: Begin searching for assistance before you run out of medication 2. **Be Persistent**: Multiple applications increase your chances of approval 3. **Ask Your Doctor**: Oncologists often have direct relationships with assistance programs 4. **Check Social Media**: Patient support groups share current program updates 5. **Document Everything**: Keep records of all applications and communications 6. **Explore Generics**: Ask if generic pazopanib is right for you 7. **Contact Your Insurance**: Appeal denials or ask about hidden benefits ## Important Legal Disclaimer This guide provides general information about medication assistance options and is not medical or legal advice. Information about programs, eligibility, and benefits is subject to change. Verify all current details directly with organizations before applying. Your healthcare provider should always be involved in treatment and medication decisions. If you have questions about your specific situation, consult with your oncologist and social worker. ## Conclusion While the manufacturer's direct program is not currently active, you have many pathways to affordable Votrient access. Don't delay treatment due to cost concerns—reach out to these resources immediately. Your healthcare team wants to help you get the medication you need.

Program information last verified: March 25, 2026